Inovio Pharmaceuticals (INO) Registration filing summary
Event summary combining transcript, slides, and related documents.
Registration filing summary
2 Jul, 2026Risk factors and disclosures
High degree of risk due to clinical, regulatory, and commercialization uncertainties; risks detailed in the prospectus, supplements, and incorporated filings.
Forward-looking statements subject to significant uncertainties, including regulatory outcomes, trial results, and financial needs.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Inovio Pharmaceuticals
- INO-3107 BLA delayed to mid-2025; Q2 net loss $32.2M, cash runway into Q3 2025.INO
Q2 20249 Jul 2026 - INO-3107 BLA submission on track, net loss narrows, and cash runway extends into 2026.INOQ4 20249 Jul 2026
- INO-3107 BLA under FDA review; FY2025 net loss narrows, cash runway into Q4 2026.INOQ4 20259 Jul 2026
- Net loss narrowed and cash runway extends into Q1 2026 as INO-3107 advances toward BLA submission.INOQ1 20258 Jul 2026
- INO-3107 showed 81% efficacy in reducing surgeries, with cash runway into Q3 2025.INOQ3 20248 Jul 2026
- INO-3107 shows strong efficacy in RRP, with regulatory review and commercial launch plans advancing.INOJefferies Global Healthcare Conference 20264 Jun 2026
- All proposals passed; focus shifts to INO-3107 FDA approval and commercial launch in 2026.INOAGM 202622 May 2026
- INO-3107 BLA under FDA review; Q1 net loss $19.7M; cash runway into Q1 2027.INOQ1 202619 May 2026
- INO-3107 for RRP shows strong efficacy and durability, with BLA submission targeted for mid-2025.INOCorporate presentation16 Apr 2026